Fibromyalgia – Management and Prescribing Guidance in Primary Care
Janus Kinase (JAK) Inhibitors and MHRA Safety Warnings
The drug pathways below includes a SWL Multi Trust Multidisciplinary Team (MDT) process. Further information and guidance on the MDT process, can be found in the ‘Payment by Results (PbR) excluded drugs/devices’ section, on the commissioning webpage.